IO Biotech (IOBTQ)
OTHER OTC:IOBTQ
Want to see IOBTQ full AI Analyst Report?
IOBTQ Stock Chart & Stats
$0.01
-$0.03(-3.11%)
At close: 4:00 PM EST
$0.01
-$0.03(-3.11%)
Day’s Range― - ―
52-Week Range<$0.01 - $2.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)22.72M
Market Cap
$589.98K
Enterprise Value-$28.32M
Total Cash (Recent Filing)$30.66M
Total Debt (Recent Filing)$1.46M
Price to Earnings (P/E)―
Beta-1.33
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding71,948,845
10 Day Avg. Volume64,845,146
30 Day Avg. Volume22,720,495
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.74
Enterprise Value/Market Cap-48.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit31.12
Enterprise Value/Ebitda0.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Combination Therapy Survival BenefitPhase 2 results showed about an eight-month median progression-free survival advantage when the investigational agent was combined with pembrolizumab, reinforcing the clinical value of the combination approach.
Phase 2 Efficacy SignalPhase 2 data demonstrated a broad antitumor signal across multiple cohorts, supporting the drug's potential as a meaningful therapeutic option and strengthening the rationale for advancing development.
Targeted Benefit In Head And Neck CancerFinal basket trial results indicated a pronounced benefit in squamous cell carcinoma of the head and neck, suggesting a focused registrational strategy in that indication could yield a clearer path to approval.
Bears Say
Approval Timeline ExtensionRequirement to design a new registrational study could extend the path to US approval by multiple years, delaying potential commercial launch and investor realization of value.
Funding And Partnership NecessityNeed to conduct an additional Phase 3 trial increases capital demands, likely necessitating external financing, strategic partnerships, or out-licensing to sustain development and execution.
Regulatory Setback RiskFDA recommendation against submitting a biologics license application after prior Phase 3 results that narrowly missed statistical significance raises the risk of prolonged regulatory hurdles and uncertainty around approval prospects.
IOBTQ FAQ
What was IO Biotech’s price range in the past 12 months?
IO Biotech lowest stock price was <$0.01 and its highest was $2.79 in the past 12 months.
What is IO Biotech’s market cap?
IO Biotech’s market cap is $589.98K.
When is IO Biotech’s upcoming earnings report date?
IO Biotech’s upcoming earnings report date is Aug 07, 2026 which is in 60 days.
How were IO Biotech’s earnings last quarter?
Currently, no data Available
Is IO Biotech overvalued?
According to Wall Street analysts IO Biotech’s price is currently Overvalued.
Does IO Biotech pay dividends?
IO Biotech does not currently pay dividends.
What is IO Biotech’s EPS estimate?
IO Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IO Biotech have?
IO Biotech has 71,948,845 shares outstanding.
What happened to IO Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IO Biotech?
Currently, no hedge funds are holding shares in IOBTQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IO Biotech
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Technical Analysis
Ownership Overview
― Insiders
0.05% Mutual Funds
1.93% Other Institutional Investors
98.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---